A securities class action lawsuit has been filed against Beta Bionics (BBNX) alleging the company failed to disclose safety issues with its iLet insulin pump, including dangerous insulin dosing and unreported complaints to the FDA. Investors who purchased stock between July 30, 2025 and February 24, 2026 have until November 3, 2026 to seek lead plaintiff status.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
